Prognostic value of platelet to lymphocyte ratio in predicting survival of patients with metastatic castration‐resistant prostate cancer receiving abiraterone acetate: An evidence‐based case report and review of literature | Zendy

Yausep Oliver E. | Zendy; Agarwal Raksheeth | Zendy; Aulina Rifqha | Zendy; Wijaya Anthony E. | Zendy; Amaia Ilonka | Zendy; Moekti Addina W. | Zendy; Rinaldi Ikhwan | Zendy; Hamid Agus Rizal A. H. | Zendy

Open Access

Prognostic value of platelet to lymphocyte ratio in predicting survival of patients with metastatic castration‐resistant prostate cancer receiving abiraterone acetate: An evidence‐based case report and review of literature

Author(s) -

Yausep Oliver E.,

Agarwal Raksheeth,

Aulina Rifqha,

Wijaya Anthony E.,

Amaia Ilonka,

Moekti Addina W.,

Rinaldi Ikhwan,

Hamid Agus Rizal A. H.

Publication year - 2019

Publication title -

clinical case reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.21

H-Index - 9

ISSN - 2050-0904

DOI - 10.1002/ccr3.2288

Subject(s) - abiraterone acetate , medicine , prostate cancer , oncology , platelet , overall survival , castration , cancer , androgen deprivation therapy , urology , hormone

Platelet to lymphocyte ratio (PLR) is a candidate prognostic marker for metastatic castration‐resistant prostate cancer patients receiving abiraterone acetate and evidence demonstrates that a high PLR is associated with poor survival. More studies are required to verify current findings and establish a definite cutoff point.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research